Immune Design Corp. (IMDZ) financial statements (2021 and earlier)
Company profile
| Business Address |
1616 EASTLAKE AVENUE E. SEATTLE, WA 98102 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in millions)
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|
| ASSETS | |||||||
| Current Assets | |||||||
| Cash, cash equivalents, and short-term investments | 96 | 141 | 107 | 113 | 75 | ||
| Cash and cash equivalents | 78 | 72 | 45 | 113 | 75 | ||
| Short-term investments | 18 | 69 | 62 | ||||
| Restricted cash and investments | 6 | ||||||
| Receivables | 1 | 4 | 4 | 1 | 2 | ||
| Inventory, net of allowances, customer advances and progress billings | 0 | 1 | 1 | 0 | 0 | ||
| Inventory | 0 | 1 | 1 | 0 | 0 | ||
| Prepaid expense | 2 | 2 | 3 | 2 | 1 | ||
| Other current assets | 2 | ||||||
| Total current assets: | 100 | 153 | 114 | 116 | 78 | ||
| Noncurrent Assets | |||||||
| Property, plant and equipment | 1 | 0 | 0 | 1 | 0 | ||
| Deposits noncurrent assets | 0 | 0 | |||||
| Total noncurrent assets: | 1 | 1 | 0 | 1 | 0 | ||
| TOTAL ASSETS: | 101 | 154 | 114 | 116 | 78 | ||
| LIABILITIES AND EQUITY | |||||||
| Liabilities | |||||||
| Current Liabilities | |||||||
| Accounts payable and accrued liabilities | 9 | 9 | 9 | 7 | 13 | ||
| Accounts payable | 1 | 2 | 5 | 3 | 7 | ||
| Accrued liabilities | 7 | 6 | 5 | 4 | 5 | ||
| Employee-related liabilities | 1 | ||||||
| Estimated litigation liability | 6 | 7 | |||||
| Deferred revenue and credits | ✕ | 3 | 0 | 1 | |||
| Other undisclosed current liabilities | (2) | ||||||
| Total current liabilities: | 9 | 15 | 19 | 7 | 12 | ||
| Noncurrent Liabilities | |||||||
| Liabilities, other than long-term debt | 0 | 0 | 0 | 0 | 0 | ||
| Deferred revenue and credits | ✕ | 0 | |||||
| Other liabilities | 0 | 0 | 0 | 0 | |||
| Total noncurrent liabilities: | 0 | 0 | 0 | 0 | 0 | ||
| Total liabilities: | 9 | 15 | 19 | 7 | 12 | ||
| Stockholders' equity | |||||||
| Stockholders' equity attributable to parent, including: | 92 | 139 | 95 | 109 | 66 | ||
| Additional paid in capital | 382 | 375 | 279 | 239 | 157 | ||
| Accumulated other comprehensive loss | (0) | (0) | (0) | ||||
| Accumulated deficit | (291) | (236) | (184) | (130) | (91) | ||
| Other undisclosed stockholders' equity attributable to parent | 0 | 0 | 0 | 0 | 0 | ||
| Total stockholders' equity: | 92 | 139 | 95 | 109 | 66 | ||
| TOTAL LIABILITIES AND EQUITY: | 101 | 154 | 114 | 116 | 78 | ||
Income statement (P&L) ($ in millions)
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|
| Revenues | 2 | 7 | 13 | 10 | 6 | |
| Revenue, net | ✕ | 7 | 13 | 10 | 6 | |
| Cost of revenue (Cost of Goods and Services Sold) | (1) | (0) | (0) | (1) | (1) | |
| Gross profit: | 1 | 7 | 13 | 9 | 6 | |
| Operating expenses | (59) | (60) | (67) | (49) | (36) | |
| Other undisclosed operating income | 1 | 0 | 0 | 1 | 1 | |
| Operating loss: | (57) | (53) | (54) | (39) | (30) | |
| Nonoperating income (Other Nonoperating income) | 2 | 1 | 1 | 0 | 0 | |
| Net loss: | (55) | (52) | (54) | (39) | (30) | |
| Other undisclosed net loss attributable to parent | (4) | |||||
| Net loss available to common stockholders, diluted: | (55) | (52) | (54) | (39) | (34) | |
Comprehensive Income ($ in millions)
| 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|
| Net loss: | (55) | (52) | (54) | (39) | (30) | |
| Comprehensive loss: | (55) | (52) | (54) | (39) | (30) | |
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 0 | (0) | (0) | |||
| Comprehensive loss, net of tax, attributable to parent: | (55) | (52) | (54) | (39) | (30) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.